This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Roman-Gomez, J. Articles by Torres, A. Search for Related Content PubMed PubMed Citation Articles by Roman-Gomez, J. Articles by Torres, A. Related Collections Commentary

CpG Island Methylator Phenotype Redefines the Prognostic Effect of t(12;21) in Childhood Acute Lymphoblastic Leukemia

Authors' Affiliations: ¹ Hematology Department, Reina Sofia Hospital, Cordoba; ² Hematology Department, Carlos Haya Hospital, Malaga; and ³ Hematology Department, Cellular Therapy Area, Clinica Universitaria/School of Medicine, Foundation for Applied Medical Research, University of Navarra, Pamplona, Spain

Requests for reprints: Jose Roman-Gomez, Hematology Department, Reina Sofia Hospital, Avda. Menendez Pidal s/n, 14004 Cordoba, Spain. Phone: 34-957-010250; Fax: 34-957-010429; E-mail: peperosa{at}teleline.es.

Purpose: To examine cancer genes undergoing epigenetic inactivation in a set of ETV6/RUNX1-positive acute lymphoblastic leukemias in order to define the CpG island methylator phenotype (CIMP) in the disease and evaluate its relationship with clinical features and outcome.

Experimental Design: Methylation-specific PCR was used to analyze the methylation status of 38 genes involved in cell immortalization and transformation in 54 ETV6/RUNX1-positive samples in comparison with 190 ETV6/RUNX1-negative samples.

Results: ETV6/RUNX1-positive samples had at least one gene methylated in 89% of the cases. According to the number of methylated genes observed in each individual sample, 20 patients (37%) were included in the CIMP– group (0-2 methylated genes) and 34 (67%) in the CIMP+ group (>2 methylated genes). Remission rate did not differ significantly among either group of patients. Estimated disease-free survival and overall survival at 9 years were 92% and 100% for the CIMP– group and 33% and 73% for the CIMP+ group (P = 0.002 and P = 0.04, respectively). Multivariate analysis showed that methylation profile was an independent prognostic factor in predicting disease-free survival (P = 0.01) and overall survival (P = 0.05). A group of four genes (DKK3, sFRP2, PTEN, and P73) showed specificity for ETV6/RUNX1-positive subset of samples.

Conclusion: Our results suggest that methylation profile may be a potential new biomarker of risk prediction in ETV6/RUNX1-positive acute lymphoblastic leukemias.

Commentary

CpG Island Methylator Phenotype and Childhood Leukemia

Norman J. Lacayo, Jorge F. DiMartino, Michael C. Wei, and Gary V. Dahl
Clin. Cancer Res. 2006 12: 4787-4789. [Full Text] [PDF]

This article has been cited by other articles:

				X. Agirre, A. Vilas-Zornoza, A. Jimenez-Velasco, J. I. Martin-Subero, L. Cordeu, L. Garate, E. San Jose-Eneriz, G. Abizanda, P. Rodriguez-Otero, P. Fortes, et al. Epigenetic Silencing of the Tumor Suppressor MicroRNA Hsa-miR-124a Regulates CDK6 Expression and Confers a Poor Prognosis in Acute Lymphoblastic Leukemia Cancer Res., May 15, 2009; 69(10): 4443 - 4453. [Abstract] [Full Text] [PDF]

				J. Roman-Gomez, X. Agirre, A. Jimenez-Velasco, V. Arqueros, A. Vilas-Zornoza, P. Rodriguez-Otero, I. Martin-Subero, L. Garate, L. Cordeu, E. San Jose-Eneriz, et al. Epigenetic Regulation of MicroRNAs in Acute Lymphoblastic Leukemia J. Clin. Oncol., March 10, 2009; 27(8): 1316 - 1322. [Abstract] [Full Text] [PDF]

				A. Inthal, G. Krapf, D. Beck, R. Joas, M. O. Kauer, L. Orel, G. Fuka, G. Mann, and E. R. Panzer-Grumayer Role of the Erythropoietin Receptor in ETV6/RUNX1-Positive Acute Lymphoblastic Leukemia Clin. Cancer Res., November 15, 2008; 14(22): 7196 - 7204. [Abstract] [Full Text] [PDF]

				R. Tomasini, K. Tsuchihara, M. Wilhelm, M. Fujitani, A. Rufini, C. C. Cheung, F. Khan, A. Itie-Youten, A. Wakeham, M.-s. Tsao, et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions Genes & Dev., October 1, 2008; 22(19): 2677 - 2691. [Abstract] [Full Text] [PDF]

				H. Kroeger, J. Jelinek, M. R. H. Estecio, R. He, K. Kondo, W. Chung, L. Zhang, L. Shen, H. M. Kantarjian, C. E. Bueso-Ramos, et al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse Blood, August 15, 2008; 112(4): 1366 - 1373. [Abstract] [Full Text] [PDF]

				J. Geli, N. Kiss, M. Karimi, J.-J. Lee, M. Backdahl, T. J. Ekstrom, and C. Larsson Global and Regional CpG Methylation in Pheochromocytomas and Abdominal Paragangliomas: Association to Malignant Behavior Clin. Cancer Res., May 1, 2008; 14(9): 2551 - 2559. [Abstract] [Full Text] [PDF]

				J. Roman-Gomez, L. Cordeu, X. Agirre, A. Jimenez-Velasco, E. San Jose-Eneriz, L. Garate, M. J. Calasanz, A. Heiniger, A. Torres, and F. Prosper Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia Blood, April 15, 2007; 109(8): 3462 - 3469. [Abstract] [Full Text] [PDF]

				N. J. Lacayo, J. F. DiMartino, M. C. Wei, and G. V. Dahl CpG Island Methylator Phenotype and Childhood Leukemia. Clin. Cancer Res., August 15, 2006; 12(16): 4787 - 4789. [Full Text] [PDF]